Anthracyclines

Priyanka Venkatesh, Anup Kasi, Priyanka Venkatesh, Anup Kasi

Excerpt

Anthracyclines are drugs extracted from Streptomyces spp. and used to treat various types of cancers. These agents are among the most effective anticancer drugs to date. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of anthracycline therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with the various cancers for which they are indicated.

Conflict of interest statement

Disclosure: Priyanka Venkatesh declares no relevant financial relationships with ineligible companies.

Disclosure: Anup Kasi declares no relevant financial relationships with ineligible companies.

Copyright © 2023, StatPearls Publishing LLC.

References

    1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun;56(2):185-229.
    1. Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, Poveda JL, Montesinos P. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert Rev Clin Pharmacol. 2019 Mar;12(3):197-218.
    1. Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Breast Cancer (Dove Med Press) 2019;11:29-42.
    1. Meyer M, Seetharam M. First-Line Therapy for Metastatic Soft Tissue Sarcoma. Curr Treat Options Oncol. 2019 Jan 24;20(1):6.
    1. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75.
    1. Chen W, Liu I, Tomiyasu H, Lee J, Cheng C, Liao AT, Liu B, Liu C, Lin C. Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line. Vet J. 2019 Dec;254:105398.
    1. Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity. Methodist Debakey Cardiovasc J. 2019 Oct-Dec;15(4):267-273.
    1. Jurczak W, Długosz-Danecka M, Szmit S. Cardio-oncology for better lymphoma therapy outcomes. Lancet Haematol. 2020 Apr;7(4):e273-e275.
    1. Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discov Today. 2017 Feb;22(2):270-281.
    1. Mukai H, Kogawa T, Matsubara N, Naito Y, Sasaki M, Hosono A. A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. Invest New Drugs. 2017 Jun;35(3):307-314.
    1. Gianni L, Viganò L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997 May;15(5):1906-15.
    1. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol. 2010 Sep 01;28(25):3901-4.
    1. Barbosa RR, Bourguignon TB, Torres LD, Arruda LS, Jacques TM, Serpa RG, Calil OA, Barbosa LFM. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers. Rev Assoc Med Bras (1992) 2018 Aug;64(8):745-754.
    1. Prasanna PL, Renu K, Valsala Gopalakrishnan A. New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci. 2020 Jun 01;250:117599.
    1. Slivnick J, Vallakati A, Addison D, Wallner A, Tong MS. Personalized Approach to Cancer Treatment-Related Cardiomyopathy. Curr Heart Fail Rep. 2020 Apr;17(2):43-55.
    1. Pituskin E, Haykowsky M, McNeely M, Mackey J, Chua N, Paterson I. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN). BMC Cancer. 2016 Sep 15;16(1):733.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever